Following the earnings announcement, several brokerage firms revised their target price for the stock, with some estimates ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

Nuvama has maintained a ‘Hold’ rating, raising its target price from Rs 1,620 to Rs 1,651. The brokerage cited strong ...

HSBC's target price implies a 13.5% upside. The brokerage retained its buy rating, as it remained positive on the medium-term ...

The drugmaker posted a profit of Rs 1,298 crore in the quarter-ended June, according to an exchange filing on Friday.

The market may continue to consolidate with a negative bias in the upcoming sessions. Below are some short-term trading ideas ...

Bank of Baroda reported net profit at Rs 4,541 crore for Q1 FY26. This marks a 2 percent rise from the Rs 4,458 crore net ...

Cipla share price gain 3% after Q1 earnings beat estimates, with strong margins, India growth, and positive analyst sentiment ...

Cipla Q1 FY26 Results Preview, Pharma Stock Price vs Nifty 50: Cipla shares are trading with cautious gains with investors ...

Cipla Ltd (BOM:500087) reports robust financial performance with significant milestones in India and strategic advancements in the US market.

Cipla consolidated net profit for the quarter ending June 2025 at ₹1291.61 crore was up 10% compared to ₹1175.46 crore in the ...

Cipla has acquired a 20% stake in iCaltech Innovations for Rs 5 crore to expand its respiratory care and diagnostics ...